Andrew Gengos Joins Terns Pharmaceuticals as Chief Financial Officer, Signaling Strategic Growth Initiative

Terns Pharmaceuticals has announced the appointment of Andrew Gengos as its new chief financial officer, effective in February 2025. The announcement marks a significant move to strengthen the company’s financial leadership as it advances clinical-stage programs in oncology and obesity treatment. CEO Amy Burroughs expressed confidence in Gengos’ background, stating that his financial leadership experience will be instrumental in driving the company’s growth trajectory and advancing its mission to transform patient care through new therapeutic options.

The appointment comes at a critical juncture as Terns progresses several clinical programs toward anticipated trial readouts. Gengos’ extensive background in the life sciences industry positions him to navigate the complex funding and operational challenges facing clinical-stage biopharmaceutical companies while positioning Terns for accelerated development and market expansion.

The Finance Executive’s Decades-Long Biotech Career Path

Andrew Gengos brings over 25 years of seasoned experience in financial leadership and corporate strategy within the life sciences sector. His career trajectory reflects a deep understanding of both the investment and operational sides of biotechnology development. Before joining Terns, Gengos served as chief financial officer at Athira Pharma, where he managed financial operations for a clinical-stage therapeutics company focused on neuroinflammatory diseases.

Prior to his role at Athira, Gengos held the position of chief business officer at Cyteir Therapeutics, where he led the finance team during the company’s transition to public markets. This experience underscores his capability to manage financial transitions and capital deployment—critical skills for a company preparing for potential inflection points in clinical development.

Gengos’ career also includes CEO positions at ImmunoCellular Therapeutics and Neuraltus Pharmaceuticals, where he provided both strategic and financial oversight across multiple therapeutic domains, including oncology and neurodegenerative disease. His earlier role as vice president of strategy and corporate development at Amgen for eight years provided exposure to large-scale pharmaceutical operations and strategic planning within one of the industry’s most established players.

His foundational experience includes positions at Morgan Stanley in investment banking and at McKinsey & Co., where he advanced from associate to senior engagement manager. This combination of Wall Street finance expertise and management consulting background has equipped him with a comprehensive toolkit for corporate strategy and financial management. He holds an M.B.A. from UCLA Anderson School of Management and a B.S. in Chemical Engineering from MIT, providing both business acumen and deep technical understanding of pharmaceutical development.

Terns’ Focus on High-Demand Treatment Areas

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing small-molecule product candidates to address serious diseases with significant unmet clinical needs. The company’s therapeutic focus centers on two major areas: oncology and obesity treatment—both representing substantial markets with growing treatment demand.

The company’s clinical-stage pipeline includes three main development programs: an allosteric BCR-ABL inhibitor for cancer treatment, a small-molecule GLP-1 receptor agonist for obesity and metabolic disease, and a THR-β agonist for additional therapeutic applications. Additionally, Terns maintains a preclinical discovery effort focused on GIPR modulators, with efforts prioritizing a GIPR antagonist as a nomination candidate. These programs position Terns at the intersection of two of healthcare’s most pressing therapeutic areas.

The appointment of a CFO with Gengos’ background suggests that Terns is preparing for significant financial milestones. Gengos himself noted optimism about the timing, stating, “I look forward to working with the talented Terns leadership team to build on the Company’s strong financial foundation” as the company “advances our lead oncology and obesity programs towards compelling clinical readouts.”

Market Response and Insider Activity

Recent insider trading activity provides insight into management’s confidence in the company’s direction. Over the six-month period preceding the announcement, Terns insiders engaged in 12 stock transactions, with 5 purchases and 7 sales. Notable transactions included purchases by Hongbo Lu (acquiring approximately 476,190 shares for an estimated $5 million) and Amy Burroughs, the CEO, who purchased approximately 15,960 shares valued at roughly $113,000. These purchases, particularly from the CEO, often signal management confidence in near-term prospects.

Conversely, the former chief financial officer Mark J. Vignola sold approximately 27,188 shares valued at around $209,000, which is consistent with typical executive transition activity.

Institutional Investors Signal Growing Interest

Institutional investment patterns reveal substantial market interest in Terns’ potential. In Q4 2024, 99 institutional investors increased their positions in Terns stock, while 85 decreased their holdings. The net inflow reflects competitive interest in the company’s pipeline potential.

Major institutional moves during this period included Morgan Stanley significantly increasing its position by adding approximately 2.56 million shares (a 327.6% increase) valued at roughly $14.2 million. Other significant position increases came from Candriam S.C.A., which added approximately 2.15 million shares (valued at approximately $11.9 million), and Soleus Capital Management, which increased its stake by adding approximately 1.92 million shares (a 30.8% increase) valued at approximately $10.6 million.

Conversely, some investors exited positions entirely. Avidity Partners Management LP divested its entire position, removing approximately 2.13 million shares valued at approximately $11.8 million, and ExodusPoint Capital Management reduced its holdings by 99.3%, selling approximately 1.64 million shares valued at approximately $9.1 million. These divergent moves reflect typical market segmentation, where some investors take profits while others see undervalued opportunity.

Strategic Implications for Company Growth

The appointment of Andrew Gengos as CFO carries multiple strategic implications for Terns’ near-term future. First, it signals to the market that management is preparing for significant operational scaling and potential catalyst events. The hiring of a finance executive with extensive public company transition experience, particularly one who has guided companies through IPOs and clinical inflection points, suggests Terns’ leadership anticipates major milestones.

Second, Gengos’ background in oncology and metabolic disease development aligns perfectly with Terns’ therapeutic focus. His familiarity with both disease areas and their corresponding market dynamics positions him to make informed capital allocation decisions as clinical data emerges.

Third, the institutional investment activity—particularly Morgan Stanley’s substantial position increase—suggests significant investor confidence in the company’s pipeline potential and Gengos’ ability to execute financially disciplined operations. The combination of new financial leadership and growing institutional support creates a favorable environment for clinical execution and potential value inflection.

The coming months will be critical for Terns, as the company moves toward clinical readouts in both its oncology and obesity programs. With Andrew Gengos’ financial expertise now guiding capital deployment and strategic planning, Terns appears positioned to translate clinical progress into sustainable business growth. His decades of biotech leadership experience and track record of navigating complex financial transitions position him to be instrumental in realizing the company’s strategic potential in high-demand treatment areas.